274 related articles for article (PubMed ID: 28427193)
41. Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma.
Xia L; Huang W; Tian D; Zhu H; Zhang Y; Hu H; Fan D; Nie Y; Wu K
J Hepatol; 2012 Sep; 57(3):600-12. PubMed ID: 22613004
[TBL] [Abstract][Full Text] [Related]
42. AURKA promotes cancer metastasis by regulating epithelial-mesenchymal transition and cancer stem cell properties in hepatocellular carcinoma.
Chen C; Song G; Xiang J; Zhang H; Zhao S; Zhan Y
Biochem Biophys Res Commun; 2017 Apr; 486(2):514-520. PubMed ID: 28322787
[TBL] [Abstract][Full Text] [Related]
43. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis.
Qi R; An H; Yu Y; Zhang M; Liu S; Xu H; Guo Z; Cheng T; Cao X
Cancer Res; 2003 Dec; 63(23):8323-9. PubMed ID: 14678992
[TBL] [Abstract][Full Text] [Related]
44. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW
Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871
[TBL] [Abstract][Full Text] [Related]
45. H2.0-like homeobox 1 acts as a tumor suppressor in hepatocellular carcinoma.
Liu T; Chen J; Xiao S; Lei X
Tumour Biol; 2016 May; 37(5):6419-28. PubMed ID: 26631039
[TBL] [Abstract][Full Text] [Related]
46. Vaccinia-related kinase 1 promotes hepatocellular carcinoma by controlling the levels of cell cycle regulators associated with G1/S transition.
Lee N; Kwon JH; Kim YB; Kim SH; Park SJ; Xu W; Jung HY; Kim KT; Wang HJ; Choi KY
Oncotarget; 2015 Oct; 6(30):30130-48. PubMed ID: 26375549
[TBL] [Abstract][Full Text] [Related]
47. Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro.
Finn RS; Aleshin A; Dering J; Yang P; Ginther C; Desai A; Zhao D; von Euw E; Busuttil RW; Slamon DJ
Hepatology; 2013 May; 57(5):1838-46. PubMed ID: 23299860
[TBL] [Abstract][Full Text] [Related]
48. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.
Arbitrario JP; Belmont BJ; Evanchik MJ; Flanagan WM; Fucini RV; Hansen SK; Harris SO; Hashash A; Hoch U; Hogan JN; Howlett AR; Jacobs JW; Lam JW; Ritchie SC; Romanowski MJ; Silverman JA; Stockett DE; Teague JN; Zimmerman KM; Taverna P
Cancer Chemother Pharmacol; 2010 Mar; 65(4):707-17. PubMed ID: 19649632
[TBL] [Abstract][Full Text] [Related]
49. CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ.
Hao X; Zhang Y; Shi X; Liu H; Zheng Z; Han G; Rong D; Zhang C; Tang W; Wang X
J Exp Clin Cancer Res; 2022 Sep; 41(1):281. PubMed ID: 36131287
[TBL] [Abstract][Full Text] [Related]
50. Zinc finger protein ZBTB20 is an independent prognostic marker and promotes tumor growth of human hepatocellular carcinoma by repressing FoxO1.
Kan H; Huang Y; Li X; Liu D; Chen J; Shu M
Oncotarget; 2016 Mar; 7(12):14336-49. PubMed ID: 26893361
[TBL] [Abstract][Full Text] [Related]
51. Overexpression and amplification of Aurora-A in hepatocellular carcinoma.
Jeng YM; Peng SY; Lin CY; Hsu HC
Clin Cancer Res; 2004 Mar; 10(6):2065-71. PubMed ID: 15041727
[TBL] [Abstract][Full Text] [Related]
52. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.
Kalous O; Conklin D; Desai AJ; Dering J; Goldstein J; Ginther C; Anderson L; Lu M; Kolarova T; Eckardt MA; Langerød A; Børresen-Dale AL; Slamon DJ; Finn RS
Breast Cancer Res Treat; 2013 Oct; 141(3):397-408. PubMed ID: 24091768
[TBL] [Abstract][Full Text] [Related]
53. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties.
Liu AM; Poon RT; Luk JM
Biochem Biophys Res Commun; 2010 Apr; 394(3):623-7. PubMed ID: 20226166
[TBL] [Abstract][Full Text] [Related]
54. A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.
Chowdhury A; Chowdhury S; Tsai MY
Leuk Lymphoma; 2012 Mar; 53(3):462-71. PubMed ID: 21879811
[TBL] [Abstract][Full Text] [Related]
55. Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway.
Tao NN; Zhou HZ; Tang H; Cai XF; Zhang WL; Ren JH; Zhou L; Chen X; Chen K; Li WY; Liu B; Yang QX; Cheng ST; Huang LX; Huang AL; Chen J
Oncotarget; 2016 Aug; 7(31):50117-50130. PubMed ID: 27367026
[TBL] [Abstract][Full Text] [Related]
56. Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells.
Lin YT; Chao CC
Oncotarget; 2015 Nov; 6(36):38999-9017. PubMed ID: 26517516
[TBL] [Abstract][Full Text] [Related]
57. RACK1 modulates apoptosis induced by sorafenib in HCC cells by interfering with the IRE1/XBP1 axis.
Zhou T; Lv X; Guo X; Ruan B; Liu D; Ding R; Gao Y; Ding J; Dou K; Chen Y
Oncol Rep; 2015 Jun; 33(6):3006-14. PubMed ID: 25901709
[TBL] [Abstract][Full Text] [Related]
58. Yap promotes hepatocellular carcinoma metastasis and mobilization via governing cofilin/F-actin/lamellipodium axis by regulation of JNK/Bnip3/SERCA/CaMKII pathways.
Shi C; Cai Y; Li Y; Li Y; Hu N; Ma S; Hu S; Zhu P; Wang W; Zhou H
Redox Biol; 2018 Apr; 14():59-71. PubMed ID: 28869833
[TBL] [Abstract][Full Text] [Related]
59. Activation of Aurora A kinase increases YAP stability via blockage of autophagy.
Wang P; Gong Y; Guo T; Li M; Fang L; Yin S; Kamran M; Liu Y; Xu J; Xu L; Peng F; Xue X; Yang M; Hung MC; Lam EW; Gu C; Wang C; Zhan Q; Liu Q
Cell Death Dis; 2019 Jun; 10(6):432. PubMed ID: 31160567
[TBL] [Abstract][Full Text] [Related]
60. RAB10 overexpression promotes tumor growth and indicates poor prognosis of hepatocellular carcinoma.
Wang W; Jia WD; Hu B; Pan YY
Oncotarget; 2017 Apr; 8(16):26434-26447. PubMed ID: 28460436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
